Epigenetic Antibodies Market to be driven by an increasing number of chronic diseases and disorders is expected to drive market expansion shortly at a CAGR of 18.00% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Epigenetic Antibodies Market” that contains information from 2019 to 2032. The Epigenetic Antibodies Market is estimated to register a CAGR of 18.00% during the forecast period of 2024 to 2032.

Market Highlights

The global Epigenetic Antibodies Market is accounted to register a CAGR of 18.00% during the forecast period and is estimated to reach USD 7.14 billion by 2032.

The growing prevalence of cancer, the aging population's increased risk of chronic diseases, rising pharmaceutical R&D costs, the growing emphasis on epigenetics in drug development, and the declining cost of genome sequencing are all factors contributing to the growth of the epigenetics antibodies market.

Key Players

MRFR recognizes the following companies as the key players in the global Epigenetic Antibodies Market— Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany).

Segment Analysis

The global Epigenetic Antibodies Market has been segmented based on Product & Service, Method, Technique, Application, and End User.

Based on Product & Service, the market is segmented into Kits & Reagents, Enzymes, Instruments and Accessories, Software, and Service. The Kits & Reagents segment was attributed to holding the largest market share in 2023. Many biotechnology companies manufacture ready-to-use kits for the detection of epigenetic modifications. There are products on the market for DNA methylation analysis and the detection of histone modifications by specific enzymes. In the early phases of therapy,

epigenetic diagnostic kits are used to detect illnesses resulting from epigenetic modifications and assess the efficacy of treatments. These kits use monoclonal antibodies to implement the immunoprecipitation principle.

Based on the Method, the Epigenetic Antibodies Market has been segmented into DNA Methylation, Histone Modifications, and Other Methods (non-coding RNA and chromatin remodeling). The DNA Methylation segment was expected to hold the largest market share in 2023. Transcription is inhibited when a methyl group is covalently added to the cytosine ring of DNA. Methylation-sensitive PCR is a PCR technique involving sensitive bisulfite modification. The ability to assess DNA methylation in a genome is becoming possible due to technological developments.

Based on the Technique, the Epigenetic Antibodies Market has been segmented into NGS, PCR & qPCR, Mass Spectrometry, Sonication, and Other Techniques (magnetic separators and microarrays). The Mass Spectrometry segment was expected to hold the largest market share in 2023. For the study of epigenetic modifications, mass spectrometry (MS) offers exceptional specificity and precision. With remarkable accuracy, it lets researchers identify and measure lots of epigenetic marks, such as DNA methylation and histone adjustments. Understanding the function of epigenetics in gene regulation, the development of ailments, and therapeutic interventions rely upon this accuracy.

Based on the Application, the Epigenetic Antibodies Market has been segmented into Oncology, Metabolic Diseases, Immunology, Developmental Biology, Cardiovascular Diseases, and Other Applications (neurology, infectious diseases, and gynecology). The Oncology segment was expected to hold the largest market share in 2023. The expansion of this class is being driven by the growing international prevalence of most cancers and the rising number of cancer-related deaths. The segment growth is also anticipated to be fueled by the launch of new products and the potential commercialization of products that can be developed in the coming years.

Based on the End User, the Epigenetic Antibodies Market has been segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Hospitals & Clinics. The Pharmaceutical & Biotechnology Companies segment was expected to hold the largest market share in 2023. The global market was dominated by pharmaceutical and biotech companies, and this trend is anticipated to persist over the projection period due to increased genetics-related R&D initiatives, as well as advancements in disease-specific therapies, drug resistance analysis in microbes, and molecular research on cancer and other disorders. To develop innovative treatments, startups and SMEs are investing in the epigenetics sector. Chroma Medicine announced intentions in November 2021 to create an epigenetic that might change the way genes produce proteins. Newpath Partners, Atlas Venture, and other investors have contributed USD 125 million to this startup. The company intends to deploy gene editing to develop pharmaceutical products. The business plans to use gene-editing techniques to develop treatments that can alter the epigenome, an important advancement in the treatment of hereditary disorders.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Epigenetic Antibodies Market Research Report

Regional Analysis

The global Epigenetic Antibodies Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The European Epigenetic Antibodies Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Epigenetic Antibodies Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Epigenetic Antibodies Market comprises of the Middle East, Africa, and Latin America.

The largest market share for the Epigenetic Antibodies Market was maintained by the North American regional sector. A large percentage is supported by the local companies' robust recognition of new product launches and improvements, the presence of key players, the well-established healthcare system, the rise in chronic diseases, and a growing old population. As in step with the U.S. Census Bureau's Population Estimates and Projections, the number of geriatric people in the country is projected to rise from 56.1 million in 2020 to over 80 million in 2040. The CDC estimates that individuals with chronic illnesses and mental health issues are responsible for 90% of the $3.8 trillion in annual healthcare charges costs in the country. The wide variety of people with chronic illnesses is anticipated to rise due to the fact this population organization's compromised immune systems lead them to be especially susceptible to many infectious and chronic illnesses.

Moreover, the Europe market has been consistently growing over the forecast period. In Europe, chronic illnesses like cancer, coronary heart ailment, and neurological situations are the main reasons for contamination. In 2022, almost one-third (36.1%) of EU citizens said they'd have an extended-term (continual) health problem. Over 1.8 million fatalities within the EU and 3.9 million deaths in Europe are attributed to cardiovascular disease (CVD) yearly. 37% of fatalities within the EU and 45% of deaths in Europe are associated with CVD. These diseases increase and enhance due in huge part to epigenetic mechanisms. The demand for antibodies that may target epigenetic markers for diagnostic and healing purposes is growing as researchers learn more about the epigenetic foundation of diverse illnesses.

The Asia-Pacific location is expected to enlarge substantially because of the provision of relatively less high-priced therapies and the upward push in medical tourism in nations like China and India. The development of a wide variety of strategic alliances between private companies and international organizations to increase their customer bases might potentially be connected to local enlargement. India has emerged as a well-liked medical tourism destination, according to the Ministry of Tourism. A total of 595,000 medical tourists visited India in 2019, up 22.3% over the previous year. India is ranked 10th out of 46 destinations worldwide in the Medical Tourism Index (MTI) for 2020–2021. Foreign Tourists Arriving for medical purposes will rise to 3.04 lakh in 2021 from 1.83 lakh in 2020.

Furthermore, the rest of the world's Epigenetic Antibodies Market is divided into the Middle East, Africa, and Latin America. MEA and LATAM areas have significant healthcare challenges because of a high incidence of infectious diseases like HIV/AIDS, TB, and malaria, in addition to non-communicable illnesses like cancer, diabetes, and cardiovascular diseases. According to a 12-month projection, there were expected to be 1.5 million new cases of cancer in Latin America and the Caribbean and 700,000 deaths from the disease, with corresponding incidence and mortality rates of 186.5 and 86.6 per 100,000. The interesting insights that epigenetic studies have revealed about the underlying mechanisms of many disorders are driving the demand for epigenetic antibodies for each research and therapy program.

Key Findings of the Study

• The global Epigenetic Antibodies Market is expected to reach USD 7.14 billion by 2032, at a CAGR of 18.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because of the rise in awareness related to epigenetics and development in infrastructure for research and clinical settings.


• Based on Product & Service, the Kits & Reagents segment was attributed to holding the largest market in 2023.


• Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), and Qiagen (Germany) are the key market players.